Nusano News

Nusano and Ariceum Therapeutics Announce Multi-Isotope Supply Agreement

Agreement includes Actinium-225 (Ac-225) and Lutetium-177 (Lu-177) to support Ariceum’s therapeutic programsWEST VALLEY CITY, Utah and BERLIN, Germany – Oct. 14, 2025 –...

Nusano Announces September 2025 Conference Schedule

Sep 4, 2025

WEST VALLEY CITY, Utah – Sept. 4, 2025 – Nusano, a leader in advanced isotope and energy technologies, today announced its September conference schedule. Nusano CEO Chris Lowe will participate in panel discussions and company leadership will be available for...

Nusano Cuts Ribbon on State-of-the-Art Radioisotope Production Facility

Aug 21, 2025

Pictured (L-R): Howard Lewin, Nusano co-founder & Chief Product Development Officer; Glenn Rosenthal, Nusano co-founder & Chief Technology Officer; Chris Lowe, Nusano CEO; John Dahlstrom, EVP, Wasatch Group; and Utah Gov. Spencer Cox. Utah Governor...

Nusano Establishes Strategic Advisory Board to Support Innovation Across Company’s Product Verticals

Aug 7, 2025

The Honorable Dr. David J. Shulkin, Corey Johnston and Seema Singh Bhan Appointed as Initial Advisory Board MembersWEST VALLEY CITY, Utah – Aug. 7, 2025 – Nusano, a physics company transforming the production of radioisotopes, today announced the formation of a...

Nusano Achieves Key Technology Milestone Enabling Simultaneous Production of Multiple Radioisotopes

Jul 9, 2025

Pairing of custom-built klystrons and fast-pulse modulators enable production of up 12 radioisotopes in a single run Power and efficiency of Nusano system to surpass existing commercial methodologies Beam time reservations and isotope supply agreements underway WEST...

Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement

Jun 26, 2025

The following is a copy of a press release issued by Cellectar BiosciencesPartnership Provides Long-Term Supply of Iodine-125 and Actinium-225 Supports Advancement of Radiotherapeutic Pipeline and Plans to Initiate Phase 1b Clinical Trial of CLR-125 for...

dGenThera and Nusano Sign Letter of Intent for Astatine‑211 Supply

Jun 19, 2025

Alpha-emitting radioisotope expected to play an essential role in next-generation targeted cancer therapies DURHAM, N.C. and WEST VALLEY CITY, Utah – June 19, 2025 – dGenThera, Inc., a biotechnology company pioneering theranostic molecular pairs, and Nusano, a...

Ratio Therapeutics and Nusano Enter Long-Term, Multi-Isotope Supply Agreement to Boost Production of Cancer Radiopharmaceuticals

Jun 17, 2025

Agreement provides Ratio access to Nusano-produced radioisotopes for oncology diagnostics and therapeutics Accelerates Ratio’s clinical pipeline with copper-64 for PET imaging and lutetium-177 and actinium-225 for targeted therapy Bolsters both companies’...

Nusano Announces Breakthrough HALEU Program Expected to Produce Up to 350 Metric Tons of Fuel Annually for Advanced Nuclear Reactors

Jun 11, 2025

Reservations available now, commercial production deliveries begin Q1 2027 Proprietary process with reduced environmental impacts Efficient domestic supply chain needed to support projected growth in energy demand from increased electrification and energy-intensive...

Nusano Stable Isotope Program Enriches Gadolinium-160 to 99.2% Purity

Jun 10, 2025

Domestic stable isotope program key to stabilizing supply chains, enabling innovation WEST VALLEY CITY, Utah – June 10, 2025 – Nusano today announced it has successfully enriched gadolinium-160 (Gd-160) to 99.2% purity, a significant milestone demonstrating the...

Registration for 2025 World Astatine Community Meeting Now Open

May 12, 2025

Radiopharmaceutical experts and researchers to gather June 19-20 in New OrleansNEW ORLEANS – May 12, 2025 – The first-ever U.S.-based meeting of the World Astatine Community will take place June 19-20, 2025 at the Sheraton in downtown New Orleans. The event will...

« Older Entries

BLOG Posts

Nusano CEO Chris Lowe on Connor Group Podcast